The current price of ACRS is $3.68 — it has decreased by 1.60% since the previous close. Data as of Nov 4, 2026.
ACRS is down 8.00% over the past week, down 16.17% over the past month and up 55.93% over the past year. The price is below its 200-day moving average of $4.54.
Analysts' average 12-month price target for ACRS is $10.50, which implies 185.33% upside from the current price. Individual estimates range from $9.00 to $12.00.
Aclaris Therapeutics, Inc. has a market capitalization of $541.69M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Aclaris Therapeutics, Inc. posted a loss of $0.15 per share against an estimate of -$0.16, beating expectations by 6.25%. Upcoming reports are listed in the earnings calendar.
Aclaris Therapeutics, Inc. reported revenue of $1.63M in its most recent quarter, which has decreased by 8.33% compared with the same quarter a year earlier. Analysts had expected $1.38M.
Companies most comparable to Aclaris Therapeutics, Inc. include First Tracks Biotherapeutics Inc, AnaptysBio, Inc., Odyssey Therapeutics, Inc., MoonLake Immunotherapeutics and Alumis Inc.
In the latest trading session ACRS moved between $3.64 and $3.87, a range of 6.25% of its current price.
Over the past 52 weeks ACRS has traded between $2.10 and $6.60. The current price is 44.24% below its 52-week high.
Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.